Search

Your search keyword '"Simsek, Ismail"' showing total 315 results
Start Over Author "Simsek, Ismail"
315 results on '"Simsek, Ismail"'

1. Sentiment Analysis of Twitter Data of Hepsiburada E-commerce Site Customers with Natural Language Processing

Author

Şimşek, İsmail, Kökçam, Abdullah Hulusi, Demir, Halil Ibrahim, Erden, Caner, Chaari, Fakher, Series Editor, Gherardini, Francesco, Series Editor, Ivanov, Vitalii, Series Editor, Haddar, Mohamed, Series Editor, Cavas-Martínez, Francisco, Editorial Board Member, di Mare, Francesca, Editorial Board Member, Kwon, Young W., Editorial Board Member, Trojanowska, Justyna, Editorial Board Member, Xu, Jinyang, Editorial Board Member, Şen, Zekâi, editor, Uygun, Özer, editor, and Erden, Caner, editor

Published
2024
Full Text
View/download PDF

7. Lorecivivint, a Novel Intraarticular CDC‐like Kinase 2 and Dual‐Specificity Tyrosine Phosphorylation‐Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial

Author

Yazici, Yusuf, McAlindon, Timothy E, Gibofsky, Allan, Lane, Nancy E, Clauw, Daniel, Jones, Morgan, Bergfeld, John, Swearingen, Christopher J, DiFrancesco, Anita, Simsek, Ismail, Tambiah, Jeyanesh, and Hochberg, Marc C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Arthritis, Chronic Pain, Clinical Trials and Supportive Activities, Aging, Cancer, Pain Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Musculoskeletal, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Imidazoles, Indazoles, Injections, Intra-Articular, Male, Middle Aged, Osteoarthritis, Knee, Pain Measurement, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases, Pyridines, Treatment Outcome, Wnt Signaling Pathway, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo assess the safety and efficacy of a novel Wnt pathway modulator, lorecivivint (SM04690), for treating pain and inhibiting structural progression in moderately to severely symptomatic knee osteoarthritis (OA).MethodsSubjects in this 52-week, phase IIa, multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial received a single 2-ml intraarticular injection of lorecivivint (dose of 0.03 mg, 0.07 mg, or 0.23 mg) or placebo. Efficacy was assessed based on change from baseline on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score subscales for pain and function (scale 0-100 for each) and change from baseline in the radiographic medial joint space width (JSW). Baseline-adjusted analysis of covariance with multiple imputation was performed separately to evaluate efficacy. This proof-of-concept study evaluated the intent-to-treat population as well as a prespecified group of subjects with unilateral symptoms of knee OA (designated UNI) and an additional post hoc subgroup of subjects with unilateral symptoms but without widespread pain (designated UNI WP-).ResultsIn this trial, 455 subjects were randomized to a treatment group. The primary end point, significant improvement in the WOMAC pain score compared with placebo at week 13, was not met by any lorecivivint dose group (mean ± SD change from baseline, -23.3 ± 2.2 in the 0.03 mg group, -23.5 ± 2.1 in the 0.07 mg group, -21.3 ± 2.2 in the 0.23 mg group, and -22.1 ± 2.1 in the placebo group; each P > 0.05 versus placebo). All groups (including placebo) demonstrated clinically meaningful (≥20-point) improvements from baseline in the WOMAC pain score. The durability of response was evaluated through week 52. In the prespecified UNI group and post hoc UNI WP- group at week 52, treatment with 0.07 mg lorecivivint significantly improved the WOMAC pain score (between-group difference versus placebo, -8.73, 95% confidence interval [95% CI] -17.44, -0.03 [P = 0.049] and -11.21, 95% CI -20.99, -1.43 [P = 0.025], respectively) and WOMAC function score (between-group difference versus placebo, -10.26, 95% CI -19.82, -0.69 [P = 0.036] and -13.38, 95% CI -24.33, -2.43 [P = 0.017], respectively). Relative to baseline, the mean change in the medial JSW at week 52 was -0.04 mm in the 0.03 mg cohort, -0.09 mm in the 0.07 mg cohort, -0.16 mm in the 0.23 mg cohort, and -0.14 mm in the placebo cohort; no treatment group achieved a significant change in medial JSW compared with placebo at week 52. In both unilateral symptom subgroups, the 0.07 mg lorecivivint dose significantly increased medial JSW compared with placebo at week 52 (medial JSW 0.39 mm, 95% CI 0.06, 0.72 in the UNI group [P = 0.021] and 0.42 mm, 95% CI 0.04, 0.80 in the UNI WP- group [P = 0.032]). Changes observed in the 0.03 mg and 0.23 mg dose groups were not significantly different from those in the placebo group for any of these measures. Lorecivivint appeared safe and well tolerated.ConclusionThis phase IIa, proof-of-concept trial in patients with symptomatic knee OA did not meet its primary end point. Nevertheless, the study identified a target population in whom to evaluate the potential efficacy of lorecivivint for the treatment of knee OA.

Published
2020

11. P104 Upregulation of both APRIL and BAFF in systemic lupus erythematosus suggests non-redundant roles, further revealed by potent dual inhibition with povetacicept (TACI vTD-Fc; ALPN-303)

Author

Lewis, Katherine E, primary, Maria, Zahra, additional, Repash, Elizabeth, additional, Blair, Tiffany C, additional, Enstrom, Amanda, additional, Evans, Lawrence S, additional, Bankhead, Armand, additional, Simsek, Ismail, additional, Peng, Stanford L, additional, and Dillon, Stacey R, additional

Published
2024
Full Text
View/download PDF

14. Acute Abdominal Aortic Occlusion in a Paraplegic Patient: Case Report.

Author

Yilmaz, Gozde, Simsek, Ismail Furkan, Aytekinc, Rukiye, Ozer, Aysegul Eylem, and Baykan, Necmi

Subjects
ABDOMINAL aorta, PARAPLEGIA, ETIOLOGY of diseases, RHABDOMYOLYSIS, NEUROLOGICAL disorders
Abstract

Copyright of Farabi Medical Journal is the property of Farabi Medical Journal and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

24. sj-pdf-1-ajs-10.1177_03635465211067201 ��� Supplemental material for Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint

Author

Tambiah, Jeyanesh R.S., Simsek, Ismail, Swearingen, Christopher J., Kennedy, Sarah, Cole, Brian J., McAlindon, Timothy E., and Yazici, Yusuf

Subjects
FOS: Clinical medicine, 110323 Surgery, 110604 Sports Medicine, FOS: Health sciences, 110314 Orthopaedics
Abstract

Supplemental material, sj-pdf-1-ajs-10.1177_03635465211067201 for Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint by Jeyanesh R.S. Tambiah, Ismail Simsek, Christopher J. Swearingen, Sarah Kennedy, Brian J. Cole, Timothy E. McAlindon and Yusuf Yazici in The American Journal of Sports Medicine

Published
2022
Full Text
View/download PDF

25. A Race Agaınst Tıme In Emergency Department: Necrotızıng Fascııtıs.

Author

Yilmaz, Gozde, Sener, Vahit, Simsek, Ismail Furkan, Baykan, Necmi, and Salt, Omer

Subjects
NECROTIZING fasciitis, HOSPITAL emergency services, SOFT tissue infections
Abstract

Necrotizing fasciitis is an important disease caused by multiple bacteria resulting in necrosis of the skin and soft tissue. Swelling, discoloration and bullae formation may be observed in the affected area. The presence of crepitation under the skin on palpation is a warning sign for necrotizing fasciitis. In our case, necrotizing fasciitis was considered as a preliminary diagnosis after a comprehensive systemic examination in a patient admitted to the emergency department with hyperglycemia. The diagnosis was confirmed by imaging, but the patient died before treatment could be started. Since the mortality rate is quite high, rapid diagnosis and initiation of treatment is very important. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

Author

Tyndall, Anthony J, Bannert, Bettina, Vonk, Madelon, Airò, Paolo, Cozzi, Franco, Carreira, Patricia E, Bancel, Dominique Farge, Allanore, Yannick, Müller-Ladner, Ulf, Distler, Oliver, Iannone, Florenzo, Pellerito, Raffaele, Pileckyte, Margarita, Miniati, Irene, Ananieva, Lidia, Gurman, Alexandra Balbir, Damjanov, Nemanja, Mueller, Adelheid, Valentini, Gabriele, Riemekasten, Gabriela, Tikly, Mohammed, Hummers, Laura, Henriques, Maria JS, Caramaschi, Paola, Scheja, Agneta, Rozman, Blaz, Ton, Evelien, Kumánovics, Gábor, Coleiro, Bernard, Feierl, Eva, Szucs, Gabriella, Von Mühlen, Carlos Alberto, Riccieri, Valeria, Novak, Srdan, Chizzolini, Carlo, Kotulska, Anna, Denton, Christopher, Coelho, Paulo C, Kötter, Ina, Simsek, Ismail, de la Pena Lefebvre, Paloma García, Hachulla, Eric, Seibold, James R, Rednic, Simona, Štork, Jiří, Morovic-Vergles, Jadranka, and Walker, Ulrich A

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results